Bain Capital Life Sciences Investors, LLC
In its 13F for Q1 2024 (holdings as of March 31, 2024, filed May 15, 2024), Bain Capital Life Sciences Investors, LLC reported 25 stock positions worth $1.2 billion. Its top holding was Newamsterdam Pharma (NAMS) at 19.9% of the portfolio, followed by Nuvalent Class A (NUVL, 16.3%) and Dianthus Therapeutics (DNTH, 7.2%). Compared with Q4 2023, it opened 2 new positions, sold out of 3, added to 3 and reduced 11. The biggest buy was a new position in Dianthus Therapeutics (DNTH) and the biggest sale Nuvalent Class A (NUVL, shares −25%).
- Most Recent 13F
- Q2 2026
- Location
- Boston, MA
- CIK
- 0001703031
- Portfolio Value
- $1.2B (Q1 2024)
- SEC Filing
- 0000950123-24-005471 ↗ filed May 15, 2024
Holdings Value
Holdings 25 stocks · $1.2B
| NAMS Newamsterdam Pharma Co. NV | 19.93% | 10,473,913 | $247.7M | No change |
| NUVL Nuvalent Inc. Class A | 16.29% | 2,697,267 | $202.5M | Reduce -24.6% |
| DNTH Dianthus Therapeutics Inc. | 7.22% | 2,992,028 | $89.8M | New |
| IRON Disc Medicine Inc. | 6.60% | 1,317,213 | $82.0M | Reduce -1.1% |
| KYTX Kyverna Therapeutics Inc. | 6.32% | 3,163,868 | $78.6M | New |
| PHVS Pharvaris NV | 6.14% | 3,303,381 | $76.3M | Reduce -15.4% |
| SVRA Savara Inc. | 5.83% | 14,565,457 | $72.5M | Add +2.3% |
| ANNX Annexon Inc. | 5.02% | 8,703,268 | $62.4M | Add +8.0% |
| SLDB Solid Biosciences Inc. | 4.32% | 4,034,582 | $53.7M | Add +28.9% |
| MDGL Madrigal Pharmaceuticals Inc. | 4.23% | 196,995 | $52.6M | Reduce -39.3% |
| MERSANA THERAPEUTICS INC | 3.12% | 8,663,673 | $38.8M | No change |
| CABA Cabaletta Bio Inc. | 2.22% | 1,617,364 | $27.6M | Reduce -19.1% |
| XFOR X4 Pharmaceuticals Inc. | 1.89% | 16,915,784 | $23.5M | No change |
| TNGX Tango Therapeutics Inc. | 1.85% | 2,892,663 | $23.0M | No change |
| ARQT Arcutis Biotherapeutics Inc. | 1.60% | 2,011,687 | $19.9M | Reduce -32.9% |
| NRIX Nurix Therapeutics Inc. | 1.34% | 1,132,397 | $16.6M | Reduce -37.9% |
| SYRS Syros Pharmaceuticals Inc. | 1.18% | 2,749,808 | $14.7M | No change |
| MRNS Marinus Pharmaceuticals Inc. | 1.01% | 1,393,380 | $12.6M | Reduce -2.6% |
| AVIR Atea Pharmaceuticals Inc. | 0.81% | 2,485,638 | $10.0M | No change |
| CCCC C4 Therapeutics Inc. | 0.75% | 1,142,210 | $9.3M | Reduce -30.4% |
| RPID Rapid Micro Biosystems Inc. Class A | 0.66% | 8,434,560 | $8.2M | No change |
| IVVD Invivyd Inc. | 0.64% | 1,799,595 | $8.0M | Reduce -7.1% |
| NAUT Nautilus Biotechnology Inc. | 0.47% | 2,000,000 | $5.9M | No change |
| ACRS Aclaris Therapeutics Inc. | 0.30% | 3,000,000 | $3.7M | Reduce -14.3% |
| XLO Xilio Therapeutics Inc. | 0.24% | 2,805,413 | $3.0M | No change |
Other holdings (1): bonds, preferreds, convertibles and warrants · $1.1M (not counted above)
| Security | Class | Shares / Principal | Value | Change |
|---|---|---|---|---|
| NAMSW Newamsterdam Pharma Co. NV-27 | *W EXP 99/99/999 | 100,000 | $1.1M | No change |
Total filed on the 13F, all lines: $1.2B.
Portfolio Sells Q4 2023 → Q1 2024
| NUVL Nuvalent Inc. Class A | Reduce -24.6% | 16.29% | −8.95 |
| PHVS Pharvaris NV | Reduce -15.4% | 6.14% | −4.36 |
| RVMD Revolution Medicines Inc. | Sold out | 0.00% | −3.06 |
| MDGL Madrigal Pharmaceuticals Inc. | Reduce -39.3% | 4.23% | −2.97 |
| NTRA Natera Inc. | Sold out | 0.00% | −2.40 |
| CABA Cabaletta Bio Inc. | Reduce -19.1% | 2.22% | −2.13 |
| IRON Disc Medicine Inc. | Reduce -1.1% | 6.60% | −0.78 |
| TSVT 2SEVENTY Bio Inc. | Sold out | 0.00% | −0.55 |
| MRNS Marinus Pharmaceuticals Inc. | Reduce -2.6% | 1.01% | −0.48 |
| NRIX Nurix Therapeutics Inc. | Reduce -37.9% | 1.34% | −0.46 |
| CCCC C4 Therapeutics Inc. | Reduce -30.4% | 0.75% | −0.14 |
| IVVD Invivyd Inc. | Reduce -7.1% | 0.64% | −0.09 |
| ACRS Aclaris Therapeutics Inc. | Reduce -14.3% | 0.30% | −0.05 |
| ARQT Arcutis Biotherapeutics Inc. | Reduce -32.9% | 1.60% | +0.67 |
Portfolio Buys Q4 2023 → Q1 2024
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 20 | $1.7B | KLRA, HTFL, NAMS, SVRA, ALKS |
| Q1 2026 | 19 | $1.1B | HTFL, NAMS, OLMA, SVRA, PHVS |
| Q4 2025 | 18 | $1.3B | HTFL, NAMS, OLMA, SVRA, PHVS |
| Q3 2025 | 20 | $1.5B | HTFL, NAMS, CDTX, PHVS, OLMA |
| Q2 2025 | 22 | $798.5M | NAMS, CDTX, NUVL, PHVS, DNTH |
| Q1 2025 | 23 | $675.0M | NAMS, NUVL, PHVS, IRON, DNTH |
| Q4 2024 | 25 | $848.7M | NAMS, NUVL, PHVS, IRON, DNTH |
| Q3 2024 | 23 | $960.5M | NUVL, NAMS, IRON, DNTH, SVRA |
| Q2 2024 | 24 | $910.0M | NUVL, NAMS, IRON, DNTH, PHVS |
| Q1 2024 | 25 | $1.2B | NAMS, NUVL, DNTH, IRON, KYTX |